Willmon Fridie Jr.

Array ( [id] => 11977612 [patent_doc_number] => 20170281767 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-05 [patent_title] => 'COMBINATION THERAPY FOR INDUCING IMMUNE RESPONSE TO DISEASE' [patent_app_type] => utility [patent_app_number] => 15/623890 [patent_app_country] => US [patent_app_date] => 2017-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 52299 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15623890 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12680971 [patent_doc_number] => 20180118823 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-03 [patent_title] => SINGLE-CHAIN MULTIVALENT BINDING PROTEINS WITH EFFECTOR FUNCTION [patent_app_type] => utility [patent_app_number] => 15/617833 [patent_app_country] => US [patent_app_date] => 2017-06-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 66399 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15617833 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16144053 [patent_doc_number] => 10705095 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-07-07 [patent_title] => Methods and products for evaluating an immune response to a therapeutic protein [patent_app_type] => utility [patent_app_number] => 15/616669 [patent_app_country] => US [patent_app_date] => 2017-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 8 [patent_no_of_words] => 20525 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 103 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15616669 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16893242 [patent_doc_number] => 11034775 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-06-15 [patent_title] => Cysteine-optimized stradomers [patent_app_type] => utility [patent_app_number] => 16/302841 [patent_app_country] => US [patent_app_date] => 2017-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 24 [patent_no_of_words] => 17944 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 103 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16302841 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15023473 [patent_doc_number] => 20190322741 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-24 [patent_title] => Methods for the Use of CD32B x CD79B-Binding Molecules in the Treatment of Inflammatory Diseases and Disorders [patent_app_type] => utility [patent_app_number] => 16/307385 [patent_app_country] => US [patent_app_date] => 2017-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26508 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16307385 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15193921 [patent_doc_number] => 10494439 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-12-03 [patent_title] => Hyperglycosylated binding polypeptides [patent_app_type] => utility [patent_app_number] => 15/614015 [patent_app_country] => US [patent_app_date] => 2017-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 39 [patent_figures_cnt] => 35 [patent_no_of_words] => 26780 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15614015 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12150186 [patent_doc_number] => 20180021451 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-01-25 [patent_title] => 'ANTIBODY-ACTIVE AGENT CONJUGATES AND METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 15/612766 [patent_app_country] => US [patent_app_date] => 2017-06-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 30938 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15612766 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14309725 [patent_doc_number] => 20190144566 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-16 [patent_title] => CYTOSOL-PENETRATING ANTIBODY AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/304444 [patent_app_country] => US [patent_app_date] => 2017-05-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31231 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 127 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16304444 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16042973 [patent_doc_number] => 10683345 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-06-16 [patent_title] => Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases [patent_app_type] => utility [patent_app_number] => 15/603259 [patent_app_country] => US [patent_app_date] => 2017-05-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 23014 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 264 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15603259 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18302073 [patent_doc_number] => 11623964 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-04-11 [patent_title] => Compositions and methods related to engineered Fc constructs [patent_app_type] => utility [patent_app_number] => 16/303831 [patent_app_country] => US [patent_app_date] => 2017-05-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 25 [patent_no_of_words] => 30092 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 298 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16303831 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16681750 [patent_doc_number] => 10941216 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-09 [patent_title] => Engineered polypeptide conjugates and methods for making thereof using transglutaminase [patent_app_type] => utility [patent_app_number] => 15/593259 [patent_app_country] => US [patent_app_date] => 2017-05-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 16 [patent_no_of_words] => 30185 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15593259 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12051224 [patent_doc_number] => 20170327569 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-16 [patent_title] => 'Novel Angiopoietin 2, VEGF Dual Antagonists' [patent_app_type] => utility [patent_app_number] => 15/593280 [patent_app_country] => US [patent_app_date] => 2017-05-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 18524 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15593280 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11943265 [patent_doc_number] => 20170247417 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-31 [patent_title] => 'T-Cell Redirecting Bispecific Antibodies for Treatment of Disease' [patent_app_type] => utility [patent_app_number] => 15/590514 [patent_app_country] => US [patent_app_date] => 2017-05-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 40425 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15590514 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12030867 [patent_doc_number] => 20170320966 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-09 [patent_title] => 'HUMANIZED MONOCLONAL ANTIBODY AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/589191 [patent_app_country] => US [patent_app_date] => 2017-05-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 10852 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15589191 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14309599 [patent_doc_number] => 20190144503 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-16 [patent_title] => METHODS FOR THE IDENTIFICATION OF BIFUNCTIONAL COMPOUNDS [patent_app_type] => utility [patent_app_number] => 16/096259 [patent_app_country] => US [patent_app_date] => 2017-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28005 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16096259 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12254227 [patent_doc_number] => 09926362 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-03-27 [patent_title] => 'Immunoglobulin constant region Fc receptor binding agents' [patent_app_type] => utility [patent_app_number] => 15/483873 [patent_app_country] => US [patent_app_date] => 2017-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 50 [patent_figures_cnt] => 69 [patent_no_of_words] => 40897 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 108 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15483873 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11963597 [patent_doc_number] => 20170267751 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-21 [patent_title] => 'PROLONGATION OF SURVIVAL OF AN ALLOGRAFT BY INHIBITING COMPLEMENT ACTIVITY' [patent_app_type] => utility [patent_app_number] => 15/476644 [patent_app_country] => US [patent_app_date] => 2017-03-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 17980 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15476644 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15290821 [patent_doc_number] => 20190388546 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-26 [patent_title] => PROCESS FOR THE PREPARATION OF PEGYLATED DRUG-LINKERS AND INTERMEDIATES THEREOF [patent_app_type] => utility [patent_app_number] => 16/088235 [patent_app_country] => US [patent_app_date] => 2017-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38545 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16088235 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14485179 [patent_doc_number] => 10329357 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-06-25 [patent_title] => Treatment of ocular disease [patent_app_type] => utility [patent_app_number] => 15/463340 [patent_app_country] => US [patent_app_date] => 2017-03-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 14424 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15463340 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16414552 [patent_doc_number] => 10822428 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-11-03 [patent_title] => Bi-and monospecific, asymmetric antibodies and methods of generating the same [patent_app_type] => utility [patent_app_number] => 15/447244 [patent_app_country] => US [patent_app_date] => 2017-03-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 46 [patent_no_of_words] => 20416 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 260 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15447244 [rel_patent_id] =>[rel_patent_doc_number] =>)